Skip to main content
AmigoFish

Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa succeeded on its primary endpoint of helping patients to see better on low luminance visual acuity in a phase three study

From BiotechTV - News · · 9 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

Chris Hollowood, Founder of Beacon and CEO of Syncona, describes the top line result and its significance. This is the first pivotal trial in X-linked retinitis pigmentosa to achieve its primary endpoint.

Back to BiotechTV - News · Report a problem